Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
439.50    6.50 (1.50%)
Bid:
432.00
Ask:
439.50
Spread: 7.50 (1.736%)
Market Cap: £216.15m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Trading Update

7 Jan 2015 07:00

RNS Number : 4767B
Zotefoams PLC
07 January 2015
 



Zotefoams plc

("Zotefoams" or "the Company")

 

Trading Update

 

7 January 2015 - Zotefoams, a world leader in cellular material technology, today provides a trading update following the Company's financial year end on 31 December 2014.

 

For the year ended 31 December 2014 Zotefoams will report sales growth in all major areas of the business with overall sales approximately 10%1 ahead of 2013 in reporting currency which is equivalent to growth of approximately 15% in constant currency.

 

In constant currency, High-Performance Products sales grew by approximately 60% while sales in MuCell Extrusion, our technology licensing business, increased by approximately 40%. Polyolefin sales volumes increased by 9% in the year, although the fourth quarter was impacted by delayed shipments. While it is normal to have some carry-over of planned shipments from month to month, the level was approximately £1.5m higher than we expected. This shortfall, which will despatch in early 2015, will result in a lower level of profitability from Polyolefin foams than previously anticipated. These delays were a result of unanticipated administrative bottlenecks following the implementation of our new ERP IT system. While we are confident that all substantive issues have now been resolved there was insufficient time to ship all orders before year end. We enter 2015 with a revenue backlog from Polyolefin foams as well as a strong order book for the start of the new year.

 

The Board expects to report an earnings outcome slightly below the lower end of market expectations when preliminary results are announced on Tuesday 17 March, 2015. With 2014 seeing strong operating profit2 growth and sales momentum into 2015, the Board remains confident of continued progress in the future.

 

 

Enquiries:

Zotefoams plc

0208-664-1600

David Stirling, Managing Director

Clifford Hurst, Finance Director

FTI Consulting

0203-727-1000

Victoria Foster Mitchell, Simon Conway

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular material technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces lightweight foams in Croydon, UK and Kentucky, USA for diverse markets worldwide through its global sales force. Zotefoams also owns and licenses patented MuCell® microcellular foam technology from a base in Massachusetts, USA to customers worldwide and sells T-Tubes® advanced insulation systems made from its patented ZOTEK® fluoropolymer foams.

 

www.zotefoams.com

 

ZOTEK® is a registered trademark of Zotefoams plc. MuCell® is a registered trademark of Trexel Inc. T-Tubes® is a registered trademark of UFP Technologies Inc.

 

 

1 Sales made by joint ventures as well as those made by Zotefoams plc and its subsidiaries.

2 Before exceptional items

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTKMGGMFVMGKZZ
Date   Source Headline
12th Apr 20214:09 pmRNSDirector/PDMR Shareholding
25th Mar 20211:26 pmRNSDirector/PDMR Shareholding
23rd Mar 20213:19 pmRNSCorrection: Preliminary Results
23rd Mar 20217:00 amRNSPreliminary Results
12th Mar 20212:53 pmRNSDirector/PDMR Shareholding
10th Mar 20211:12 pmRNSHolding(s) in Company
9th Mar 20213:13 pmRNSHolding(s) in Company
9th Mar 20213:05 pmRNSHolding(s) in Company
9th Mar 20211:55 pmRNSHolding(s) in Company
8th Mar 20213:04 pmRNSResult of secondary placing in Zotefoams plc
8th Mar 202112:00 pmRNSProposed secondary placing in Zotefoams plc
8th Mar 20217:00 amRNSNotice of results and investors presentation
5th Mar 20214:36 pmRNSPrice Monitoring Extension
23rd Feb 20217:00 amRNSProduction starts at new £23m plant in Poland
15th Feb 20217:00 amRNSPolish factory virtual tour and investor Q&A
12th Feb 20214:20 pmRNSDirector/PDMR Shareholding - Replacement
12th Feb 20213:54 pmRNSDirector/PDMR Shareholding
12th Feb 20213:38 pmRNSDirector/PDMR Shareholding
8th Feb 20214:41 pmRNSSecond Price Monitoring Extn
8th Feb 20214:35 pmRNSPrice Monitoring Extension
21st Jan 20217:00 amRNSOperational and Trading Update
12th Jan 20213:50 pmRNSDirector/PDMR Shareholding
14th Dec 20204:19 pmRNSDirector/PDMR Shareholding
12th Nov 20203:40 pmRNSDirector/PDMR Shareholding
5th Nov 20207:00 amRNSOperational and Trading Update
22nd Oct 202010:36 amRNSDirector/PDMR Shareholding
14th Oct 20207:00 amRNSDirector/PDMR Shareholding
9th Oct 20207:00 amRNSDirector/PDMR Shareholding
7th Oct 20207:00 amRNSExternal Auditor Appointment
1st Oct 20204:13 pmRNSDirector/PDMR Shareholding
16th Sep 20204:29 pmRNSDirector/PDMR Shareholding
11th Sep 20204:41 pmRNSSecond Price Monitoring Extn
11th Sep 20204:35 pmRNSPrice Monitoring Extension
9th Sep 20205:51 pmRNSHolding(s) in Company
1st Sep 20204:40 pmRNSSecond Price Monitoring Extn
1st Sep 20204:35 pmRNSPrice Monitoring Extension
18th Aug 202010:54 amRNSDirector/PDMR Shareholding
12th Aug 20203:52 pmRNSDirector/PDMR Shareholding
11th Aug 20207:00 amRNSInterim Results
14th Jul 20207:00 amRNSDirector/PDMR Shareholding
9th Jul 20204:35 pmRNSPrice Monitoring Extension
9th Jul 20207:00 amRNSNotice of Results
16th Jun 20205:05 pmRNSHolding(s) in Company
12th Jun 20203:25 pmRNSDirector/PDMR Shareholding
8th Jun 20202:06 pmRNSResult of the 2020 Annual General Meeting
2nd Jun 20208:00 amRNSOperational and Trading Update
22nd May 202012:07 pmRNSSecond Price Monitoring Extn
22nd May 202012:02 pmRNSPrice Monitoring Extension
14th May 20203:48 pmRNSIssue of Equity
14th May 20203:15 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.